Tandem Diabetes Care filings document the company’s insulin delivery business, Nasdaq-listed common stock, operating results, governance matters, and capital structure. Recent 8-K reports furnish quarterly and annual financial results, guidance-related disclosures, and product or regulatory events tied to its diabetes technology portfolio.
The filing record also includes proxy materials for annual meeting voting, director elections, executive compensation, equity awards, and board committee matters. Material-event filings describe the company’s completed 0.00% convertible senior notes offering, related indenture terms, and FDA clearance for the SteadiSet wearable infusion set.
Elizabeth A. Gasser, EVP and Chief Strategy Officer of Tandem Diabetes Care, reported multiple transactions on 08/15/2025 affecting her holdings of TNDM common stock. She acquired 1,503 shares (RSU vesting) and an additional 1,097 shares (RSU vesting), both reported as acquisitions at $0 per share. To satisfy tax withholding on vesting, 805 and 588 shares were withheld and disposed at $10.82 per share; no shares were sold on the open market. She directly beneficially owns 4,509 shares from vested RSUs and 7,677 shares from other RSUs per the table, and indirectly holds 22,949 shares through The Gasser Family Trust, where she is a co-trustee.
John F. Sheridan, President & CEO and director of Tandem Diabetes Care, Inc. (TNDM), reported a non-derivative purchase of 10,000 shares on 08/11/2025. The filing states the trades executed at prices ranging from $10.19 to $10.33, with a weighted average purchase price of $10.2318. Following the reported transaction, the reporting person beneficially owned 106,327 shares.
The Form 4 identifies the filing as by one reporting person and includes an explanatory note that full details of the multiple trades (number of shares per trade and individual prices) will be provided upon request. The form is signed by Rachel Malina as attorney-in-fact for John F. Sheridan.
Diabetes Care Inc EVP & Chief Financial Officer Leigh Vosseller reported an open-market purchase of common stock on August 8, 2025. A trust bearing her name bought 13,720 shares at a weighted average price of $10.8895 per share, through multiple trades between $10.86 and $10.90.
After this transaction, the trust holds 25,580 shares indirectly, while Vosseller also holds 33,798 shares directly. The filing notes that the securities are held by the Leigh A. Vosseller Trust, for which she serves as trustee.
Tandem Diabetes Care (NASDAQ:TNDM) filed a routine Form 4 reporting Chief Technology Officer Rick Carpenter’s latest equity transaction.
On June 16 2025, Carpenter acquired 406 common shares through the vesting of previously granted restricted stock units (RSUs) at a stated price of $0. To cover statutory tax withholding, 207 shares were automatically withheld by the company and disposed of at $20.76 per share. Following the transactions, Carpenter directly owns 21,219 shares of Tandem Diabetes Care common stock.
The filing indicates these transfers were executed under the company’s 2013 Stock Incentive Plan and do not involve open-market purchases or sales. No additional derivative positions were reported beyond the RSU conversion.
SEC Form 4 filed on 06/18/2025 reveals that Tandem Diabetes Care, Inc. (TNDM) director Myoungil Cha acquired 1,749 shares of common stock on 06/16/2025 through the vesting and settlement of previously granted restricted stock units (RSUs) under the company’s 2013 Stock Incentive Plan. The conversion, reported with transaction code “M,” was executed at $0 cost to the insider and involved no open-market purchase or sale.
Following the transaction, Cha’s direct beneficial ownership rose from 11,950 to 13,699 shares. The RSU grant was originally awarded on 06/15/2022 and vests in three equal annual installments; the reported shares represent the second installment, with additional tranches scheduled for future anniversaries, subject to plan terms.
Key takeaways:
- Insider ownership increase: +1,749 shares, signalling continued alignment with shareholder interests.
- Routine equity compensation: Transaction stems from standard RSU vesting, not discretionary market activity.
- No cash proceeds or sales: Neutral impact on near-term share flow and insider liquidity.
Form 4 filing: On 18-Jun-2025 Tandem Diabetes Care (TNDM) reported that director Joao Paulo Falcao Malagueira acquired 1,749 common shares on 16-Jun-2025 through the automatic settlement of previously granted restricted stock units (RSUs). The RSUs were awarded on 15-Jun-2022 under the company’s 2013 Stock Incentive Plan and vest in three equal annual instalments. No cash consideration was paid (exercise price $0).
Following the conversion, the director’s direct ownership increases to 13,699 TNDM shares. The transaction is coded “M,” indicating a routine equity award vesting rather than an open-market trade, and leaves no remaining derivative securities from this grant. The filing does not signal any strategic or operational changes at the company.